Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

Dallalzadeh, Liane O.; Ozzello, Daniel J.; Liu, Catherine Y.; Kikkawa, Don O.; Korn, Bobby S.

doi:10.1080/01676830.2021.1903044

Cited by 82 publications

(81 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We cannot exclude a prior undocumented, untreated, or asymptomatic infection with SARS-CoV-2 in the other half. Multiple case reports and series (10)(11)(12)(13)(14) from different parts of the world have described ROCM-or invasive maxillofacial fungal infection-in SARS-CoV-2-positive patients but with no evidence of an actual spike in case numbers.…”

Section: Discussionmentioning

confidence: 99%

Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Objective: To determine if there was an increase in the rate of cases presenting with rhino-orbital-cerebral mucormycosis (ROCM) to a tertiary care center during the first wave of the coronavirus disease 2019 (COVID-19) pandemic and the characteristics of the presenting cases.Methods: Retrospective observational study reviewing ROCM cases presenting from March 25 until September 25, 2020. Cases fulfilling the clinical, radiological, and pathological/microbiological criteria for diagnosis with ROCM were included. The number of cases presenting during the designated interval, their COVID-19 status, comorbidities, and clinical presentation were analyzed. The number of cases during the corresponding interval in the previous 3 years was used as reference to detect if there was a recent spike.Results: Of the 12 ROCM cases identified, 5 had a concurrent positive reverse transcription PCR (RT-PCR) test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1 had a prior positive result, and 6 did not have concurrent nor prior positive test results. Nine of the 12 cases had poorly controlled diabetes mellitus, and 2 cases had a hematological malignancy. All cases had orbital invasion, and eight cases had cerebral invasion. The number of cases identified during the interval is much higher than the numbers presenting in the prior 3 years during equivalent intervals (range, one to two cases) than those reported in the literature in different settings in the pre-pandemic era.Conclusions: There is an increased rate of ROCM cases presenting to our center during the first wave of the COVID-19 pandemic. This is a preliminary report, and further studies are needed to corroborate the findings and explain possible underlying links.

show abstract

Section: Discussionmentioning

confidence: 99%

Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The clinical manifestations of patients with COVID-19 infection are common in both waves: fever, cough, fatique and shortness of breath [1]. The second wave has also came across features like headache, localised pain, nasal discharge, sinusitis, orbital cellulitis and dimuniation of vision due to rhino-orbital fungal infection occuring few weeks after recovery of COVID-19 patients [3][4][5]. Fungal infection mainly affects people on medication due to their reduced ability to fight environmental pathogens [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Post Covid-19 Infection Presenting as Rhino-Orbital Mycosis

Garg¹,

Bharangar²,

Bhardwaj³

2021

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Rhino-orbital mycosis has been recently recognised as one of the sequelae in COVID-19 recovered patients. In India, detection of mucormycosis is declared as notifiable disease. In this article, the authors aim to describe the characteristics of patients presenting with post covid fungal infection which could be detected on 10% potassium hydroxide (KOH) wet mount and Giemsa stain put on crush biopsy smear. We describe 10 COVID-19 recovered patients admitted to ENT department of the hospital during second wave of COVID-19 infection. They presented with post covid fungal sinusitis and ophthalmic complications and planned for surgery. KOH mount and Giemsa stain were used for possible opinion and confirmed by culture. The observations were described in mean and percentages. All ten (100%) COVID-19 recovered patients were previously diagnosed with type 2 diabetes mellitus (DM) for 2-11 years. All 10 patients (100%) were given oral or intravenous corticosteroids for mean of 21 days (3 weeks-till presentation to ENT department). Simple procedures with 10% KOH mount and Giemsa stain could detect fungal hypae in all the cases and could provide possible opinion in 9 of 10 (90%) cases for timely management of the patients. The authors hypothesize that uncontrolled DM and prolonged use of corticosteroids may act as culprits of rhino-orbital mycosis in COVID-19 recovered patients. Simple and routine 10% KOH mount and Giemsa stain may provide early opinion of fungal hypae to ensure quick management and survival of the patients.

show abstract

“…The increasing number of recent case series of mucormycosis complicating COVID-19 patients in the United States, 10 – 16 Austria, 17 Brazil, 18 Mexico, 19 Italy, 20 France, 21 Iran, 22 – 24 and India, 25 – 34 raises concerns regarding the misuse of immunosuppressive drugs in patients with COVID-19. Mucormycosis is a neglected mycosis that should be considered in the context of patients with COVID-19, in the same way as COVID-19 associated pulmonary aspergillosis, and it is possibly underreported.…”

mentioning

confidence: 99%

“…Classically, uncontrolled diabetes mellitus, neutropenia, and corticosteroid therapy are known risk factors for mucormycosis. 22 , 37 There is an urgent need to reconsider the careful use of these drugs in patients with severe COVID-19 due to the high prevalence of underlying comorbidities in these patients, 11 – 13 , 25 , 28 – 30 including diabetes mellitus, 13 , 16 , 19 , 26 , 28 – 30 hematological malignancies (i.e. acute myeloid leukemia), 17 end-stage kidney disease, 27 and organ transplant recipients.…”

mentioning

confidence: 99%

COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs

Rodríguez-Morales

Sah

Millán-Oñate³

et al. 2021

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

Cited by 82 publications

References 11 publications

Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic

Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic

Post Covid-19 Infection Presenting as Rhino-Orbital Mycosis

COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs

Contact Info

Product

Resources

About